دورية أكاديمية
أعرض في EDS

Population-Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis.

التفاصيل البيبلوغرافية
العنوان: Population-Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis.
المؤلفون: Witzel S; Department of Neurology, Ulm University, Ulm, Germany., Huss A; Department of Neurology, Ulm University, Ulm, Germany., Nagel G; Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany., Rosenbohm A; Department of Neurology, Ulm University, Ulm, Germany., Rothenbacher D; Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany., Peter RS; Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany., Bäzner H; Department of Neurology, Klinikum Stuttgart, Katharinenhospital, Stuttgart, Germany., Börtlein A; Department of Neurology, Klinikum Stuttgart, Katharinenhospital, Stuttgart, Germany., Dempewolf S; Department of Neurology, RKH Klinikum Ludwigsburg, Ludwigsburg, Germany., Schabet M; Department of Neurology, RKH Klinikum Ludwigsburg, Ludwigsburg, Germany., Hecht M; Department of Neurology, Klinikum Kaufbeuren, Kliniken Ostallgaeu-Kaufbeuren, Kaufbeuren, Germany., Kohler A; Department of Neurology, Klinikum am Gesundbrunnen Heilbronn, Heilbronn, Germany., Opherk C; Department of Neurology, Klinikum am Gesundbrunnen Heilbronn, Heilbronn, Germany., Naegele A; Department of Neurology, Christophsbad Goeppingen, Göppingen, Germany., Sommer N; Department of Neurology, Christophsbad Goeppingen, Göppingen, Germany., Lindner A; Department of Neurology, Marienhospital Stuttgart, Stuttgart, Germany., Alexudis C; Department of Neurology, Ulm University, Ulm, Germany., Bachhuber F; Department of Neurology, Ulm University, Ulm, Germany., Halbgebauer S; Department of Neurology, Ulm University, Ulm, Germany.; German Center for Neurodegenerative Diseases (DZNE), Site Ulm, Ulm, Germany., Brenner D; Department of Neurology, Ulm University, Ulm, Germany., Ruf W; Department of Neurology, Ulm University, Ulm, Germany., Weiland U; Department of Neurology, Ulm University, Ulm, Germany., Mayer B; Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany., Schuster J; Department of Neurology, Ulm University, Ulm, Germany.; German Center for Neurodegenerative Diseases (DZNE), Site Ulm, Ulm, Germany., Dorst J; Department of Neurology, Ulm University, Ulm, Germany., Tumani H; Department of Neurology, Ulm University, Ulm, Germany.; German Center for Neurodegenerative Diseases (DZNE), Site Ulm, Ulm, Germany., Ludolph AC; Department of Neurology, Ulm University, Ulm, Germany.; German Center for Neurodegenerative Diseases (DZNE), Site Ulm, Ulm, Germany.
مؤلفون مشاركون: ALS Registry Swabia Study Group
المصدر: Annals of neurology [Ann Neurol] 2024 Aug 23. Date of Electronic Publication: 2024 Aug 23.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7707449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8249 (Electronic) Linking ISSN: 03645134 NLM ISO Abbreviation: Ann Neurol Subsets: MEDLINE
أسماء مطبوعة: Publication: New York, NY : Wiley-Liss
Original Publication: Boston, Little, Brown.
مستخلص: Objective: Neurofilament light chains (NfL) and phosphorylated neurofilament heavy chains (pNfH), established as diagnostic and prognostic biomarkers in hospital-based amyotrophic lateral sclerosis (ALS) cohorts, are now surrogate markers in clinical trials. This study extends their evaluation to a population level, with the aim of advancing their full establishment and assessing the transferability of biomarker findings from controlled cohorts to real-world ALS populations.
Methods: We measured serum NfL and pNfH levels in all ALS patients (n = 790) and general population controls (n = 570) with available baseline samples participating in the epidemiological ALS Registry Swabia, providing platform-specific (ELLA™) reference data and Z-scores for controls, as well as reference data, disease-specific Z-scores and longitudinal data in ALS. We evaluated the diagnostic and prognostic utility of neurofilaments and quantified the impact of ALS-related factors and non-ALS confounders.
Results: Neurofilaments showed high diagnostic and prognostic utility at the population level, with NfL superior to pNfH. The novel concept of a population-based ALS Z-score significantly improved the prognostic utility compared to absolute raw values. Both biomarkers increased more strongly with age in controls than in ALS, and age adjustment improved diagnostic accuracy. Our data show that disease progression rates, ALS phenotype, body mass index (BMI), and renal function need to be considered when interpreting neurofilament levels; longitudinal neurofilament levels were generally stable in individual patients, especially when adjusted for age and baseline levels.
Interpretation: Population-based assessment enhances the utility of particularly serum NfL as a diagnostic and prognostic biomarker in ALS and improves the translation of findings from controlled cohorts to real-world populations. ANN NEUROL 2024.
(© 2024 The Author(s). Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
References: Yuan A, Rao MV, Veeranna NRA. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harbor Perspect Biol 2017;9:a018309. https://doi.org/10.1101/cshperspect.a018309.
Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577–589. https://doi.org/10.1038/s41582-018-0058-z.
Mattsson N, Cullen NC, Andreasson U, et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2019;76:791–799. https://doi.org/10.1001/JAMANEUROL.2019.0765.
Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun 2021;12:3400. https://doi.org/10.1038/s41467-021-23620-z.
Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 2020;95:59–69. https://doi.org/10.1212/WNL.0000000000009559.
Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019;90:157–164. https://doi.org/10.1136/jnnp-2018-318704.
Halbgebauer S, Steinacker P, Verde F, et al. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J Neurol Neurosurg Psychiatry 2022;93:68–74. https://doi.org/10.1136/jnnp-2021-327129.
De Schaepdryver M, Jeromin A, Gille B, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2018;89:367–373. https://doi.org/10.1136/jnnp-2017-316605.
Thouvenot E, Demattei C, Lehmann S, et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol 2020;27:251–257. https://doi.org/10.1111/ene.14063.
Gille B, De Schaepdryver M, Goossens J, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol Appl Neurobiol 2019;45:291–304. https://doi.org/10.1111/nan.12511.
Witzel S, Frauhammer F, Steinacker P, et al. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Transl Neurodegener 2021;10:31. https://doi.org/10.1186/s40035-021-00257-y.
Lu C‐H, Macdonald‐Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247–2257. https://doi.org/10.1212/WNL.0000000000001642.
Steinacker P, Huss A, Mayer B, et al. Diagnostic and prognostic significance of neurofilament light chain NF‐L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND‐net. Amyotrophic Lateral Scler Frontotemporal Degener 2017;18:112–119. https://doi.org/10.1080/21678421.2016.1241279.
Behzadi A, Pujol‐Calderón F, Tjust AE, et al. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. Sci Rep 2021;11:22128. https://doi.org/10.1038/s41598-021-01499-6.
Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 2018;90:e22–e30. https://doi.org/10.1212/WNL.0000000000004761.
Brousse M, Delaby C, De La Cruz E, et al. Serum neurofilament light chain cut‐off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis. Eur J Neurol 2023;30:1919–1927. https://doi.org/10.1111/ENE.15813.
Meyer T, Salkic E, Grehl T, et al. Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis—a cross‐sectional multicenter study. Eur J Neurol 2023;30:1600–1610. https://doi.org/10.1111/ENE.15773.
Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2022;387:1099–1110. https://doi.org/10.1056/NEJMOA2204705/SUPPL_FILE/NEJMOA2204705_DATA-SHARING.PDF.
Mullard A. NfL makes regulatory debut as neurodegenerative disease biomarker. Nat Rev Drug Discov 2023;22:431–434. https://doi.org/10.1038/D41573-023-00083-Z.
Dorst J, Schuster J, Dreyhaupt J, et al. Effect of high‐caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2020;91:1007–1009. https://doi.org/10.1136/jnnp-2020-323372.
Wong C, Stavrou M, Elliott E, et al. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun 2021;3. https://doi.org/10.1093/BRAINCOMMS/FCAB242.
Surrogate Endpoint Resources for Drug and Biologic Development | FDA. [date unknown].
Truffi M, Garofalo M, Ricciardi A, et al. Neurofilament‐light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study; 4041 https://doi.org/10.1038/s41598-023-29704-8.
Gauthier A, ebastien Viel S, Perret M, et al. Comparison of Simoa TM and Ella TM to assess serum neurofilament‐light chain in multiple sclerosis. Ann Clin Transl Neurol 2021;8:1141–1150. https://doi.org/10.1002/acn3.51355.
Benkert P, Meier S, Schaedelin S, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 2022;21:246–257. https://doi.org/10.1016/S1474-4422(22)00009-6.
Nagel G, Ünal H, Rosenbohm A, et al. Implementation of a population‐based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) ‐ registry Swabia. BMC Neurol 2013;13:22. https://doi.org/10.1186/1471-2377-13-22.
Uenal H, Rosenbohm A, Kufeldt J, et al. Incidence and geographical variation of amyotrophic lateral sclerosis (ALS) in southern Germany – completeness of the ALS registry Swabia. PLoS One 2014;9:e93932. https://doi.org/10.1371/journal.pone.0093932.
Rosenbohm A, Peter RS, Erhardt S, et al. Epidemiology of amyotrophic lateral sclerosis in southern Germany. J Neurol 2017;264:749–757. https://doi.org/10.1007/s00415-017-8413-3.
Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962;51:224–232.
Deurenberg P, Andreoli A, Borg P, et al. The validity of predicted body fat percentage from body mass index and from impedance in samples of five European populations. Eur J Clin Nutr 2001;55:973–979. https://doi.org/10.1038/SJ.EJCN.1601254.
Grubb A, Horio M, Hansson LO, et al. Generation of a New Cystatin C–Based Estimating Equation for Glomerular Filtration Rate by Use of 7 Assays Standardized to the International Calibrator. Clin Chem 2014;60:974–986. https://doi.org/10.1373/CLINCHEM.2013.220707.
Westeneng H‐J, Debray TPAA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018;17:423–433. https://doi.org/10.1016/S1474-4422(18)30089-9.
Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig 2014;4:605–618. https://doi.org/10.4155/cli.14.52.
Thakore NJ, Lapin BR, Pioro EP. Trajectories of impairment in amyotrophic lateral sclerosis: insights from the pooled resource open‐access ALS clinical trials cohort. Muscle Nerve 2018;57:937–945. https://doi.org/10.1002/mus.26042.
Fournier C, Glass JD. Modeling the course of amyotrophic lateral sclerosis. Nat Biotechnol 2015;33:45–47. https://doi.org/10.1038/nbt.3118.
Maier A, Boentert M, Reilich P, et al. ALSFRS‐R‐SE: an adapted, annotated, and self‐explanatory version of the revised amyotrophic lateral sclerosis functional rating scale. Neurol Res Pract 2022;4. https://doi.org/10.1186/S42466-022-00224-6.
Corcia P, Lunetta C, Vourc'h P, et al. Time for optimism in amyotrophic lateral sclerosis. Eur J Neurol 2023;30:1459–1464. https://doi.org/10.1111/ENE.15738.
Baumgartner D, Mazanec R, Hanzalová J. Diagnostic utility of neurofilament markers for MND is limited in restricted disease phenotype and for differentiation from compressive myeloradiculopathies. J Neurol 2023;270:1600–1614. https://doi.org/10.1007/S00415-022-11504-1.
Khalil M, Pirpamer L, Hofer E, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun 2020;11:812. https://doi.org/10.1038/s41467-020-14612-6.
Manouchehrinia A, Piehl F, Hillert J, et al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol 2020;7:139–143. https://doi.org/10.1002/acn3.50972.
Akamine S, Marutani N, Kanayama D, et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep 2020;10:20350. https://doi.org/10.1038/s41598-020-76990-7.
Zhu Y, Yang M, Li F, et al. Aberrant levels of cystatin C in amyotrophic lateral sclerosis: a systematic review and meta analysis. Int J Biol Sci 2018;14:1041–1053. https://doi.org/10.7150/ijbs.25711.
Nagel G, Kurz D, Peter RS, et al. Cystatin C based estimation of chronic kidney disease and amyotrophic lateral sclerosis in the ALS registry Swabia: associated risk and prognostic value. Sci Rep 2023;13:19594. https://doi.org/10.1038/s41598-023-46179-9.
Benatar M, Wuu J, Andersen PM, et al. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol 2018;84:130–139. https://doi.org/10.1002/ana.25276.
Dorst J, Chen L, Rosenbohm A, et al. Prognostic factors in ALS: a comparison between Germany and China. J Neurol 2019;266:1516–1525. https://doi.org/10.1007/s00415-019-09290-4.
Tang L, Dorst J, Chen L, et al. A natural history comparison of SOD1‐mutant patients with amyotrophic lateral sclerosis between Chinese and German populations. Transl Neurodegener 2021;10:42. https://doi.org/10.1186/s40035-021-00266-x.
معلومات مُعتمدة: 577631 Deutsche Forschungsgemeinschaft
فهرسة مساهمة: Investigator: B Alber; F Andres; G Arnold; I Asshauer; H Baezner; H Baier; J Baumgärtner; J Beattie; T Becker; F Behne; D Bengel; C Bergmeier; A Boertlein; C Born; V Bracknies; R Broer; M Bürgy; M Buttmann; M Clauer-Bredt; B Connemann; S Dempewolf; K Demuth; C Dettmers; M Dieterich; E Etzersdorfer; F Ch; W Freund; H Friederich; M Gahr; T Gasser; J Gebhardt; I Gecui; T Gersner; F Geser; A Gogolkiewicz; HJ Gold; R Greber; H Grunze; W Hacke; G Hamann; M Hecht; B Heimbach; B Hemmer; C Hendrich; K Henkel; B Herting; W Hewer; G Höglinger; R Huber; K Huber-Hartmann; PJ Huelser; M Jöbges; A Jonuz; A Joos; E Jüttler; J Kammerer-Ciernioch; A Kaspar; R Kern; H Kimmig; S Klebe; C Kloetzsch; T Klopstock; M Köhler; A Kohler; R Kozian; A Kuethmann; C Laske; D Lewis; C Lichy; A Lindner; P Lingor; D Lulé; W Maier-Janson; M Mäurer; J Metrikat; O Meudt; A Meyer; A Michaelides; J Müller Vom Hagen; M Munk; A Naegele; M Naumann; KD Neher; O Neuhaus; C Neusch; L Niehaus; A Niestroj; C Opherk; E Pinkhardt; J Raape; P Ratzka; M Reinhard; C Rettenmayr; MW Riepe; J Rothmeier; M Ruchsow; M Sabolek; M Schabet; M Schaeff-Vogelsang; C Schell; A Schläger; T Schlipf; M Schmauss; L Schoels; K Schöneberger-Stroick; K Schörner; K Schuetz; B Schweigert; C Sheka; N Sommer; S Spannhorst; W Sperber; C Steber; R Steber; M Stroick; M Synofzik; C Thomas; T Trottenberg; H Tumani; N Vasic; J Volkmann; C Wahl; F Weber; M Weiler; C Weiller; C Wessig; W Wick; A Winkler; D Zeller
تواريخ الأحداث: Date Created: 20240823 Latest Revision: 20240823
رمز التحديث: 20240823
DOI: 10.1002/ana.27054
PMID: 39177232
قاعدة البيانات: MEDLINE
الوصف
تدمد:1531-8249
DOI:10.1002/ana.27054